PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Liu M, Bagnasco D, Matucci A, et al. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. 8. 2. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF- Trap/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC), 3. 12. Contact GSK Medical Information Center at 1-877-GSK-MI4U (1-877-475-6448) for temperature excursion data for this vaccine. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. 2014;123(20):3128-3138. Poster No. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Mularski RA, Drummond MB, Jain R, et al. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. 1053; Abstract A5058]. Silver J, Deb A, Packnett E, et al. Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) Prescribing Information Patient Information www.vaxelis.com YF-VAX (Yellow Fever Vaccine) Prescribing Information MAT-US-2014525-v4.-05/2022 Last Update: May 2022 2. temperature stability) related questions for Amgen products. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. 2. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. . POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. Cho E-Y, Cho J-E, Jang S-H, et al. 1. Pitrez P, Bruselle G, Yorgancolu A, et al. Efficacy and Safety of Niraparib in Elderly Patients (Pts) with Advanced Ovarian Cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 Trial, 4. 2. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. 4. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. Eur J Cancer. Discard if the vaccine has been frozen. DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMMOutcomes by Prior Therapies [Poster not available for viewing due to copyright restrictions], 6. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. P1440. 5. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. 1. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. 1. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. 7. Soler X, Siddall J, Small M, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. 2. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. 4. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Expert Opin Ther Targets. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Bogart M, Wu B, Germain G, et al. Sanofi Pasteur 800-822-2463 . OConnor BP, Raman VS, Erikson LD, et al. Slade D, Ray R, Moretz C, et al. Ismaila A, Haeussler K, Czira A, et al. Initiating Mepolizumab. 7. (2.1) Do not dilute or mix with any other insulin or solution. [Poster No. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. 10. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Verhamme K, de Ridder M, Webb D, et al. Poster No. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. Cancer Immunol Immunother. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. This indicates that the vaccine has experienced a temperature excursion and references this report; b) If the expiration date of the vaccine has changed, clearly indicate the new expiration date on the package; and c) Return the vaccine to your inventory. Seo J, Zhang S, Zhang D, et al. Poster No. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. 3. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. 2017;47(5):765-779. [Oral presentation available here; Abstract A4209]. Singh T et al. 7. Sorry to interrupt Close this window. Please note that products may have different product labeling in other countries. Vaccine Stability Calculator Prevnar 13 Prevnar 20. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. 2017;276(1):80-96. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. Liu M, Bagnasco D, Matucci A, et al. Association between TGF- signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Fever - The percentage of temperature measurements that were taken by oral route or not recorded were 97.9% and 2.1%, respectively, for FLUZONE High-Dose; and 98.6% and 1.4%, respectively, for FLUZONE Data from Post-Marketing Experience The following additional events have been reported during the post-approval use of FLUZONE [Poster No. [Poster No. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. 2018;22(6):527-545. Keeley T, et al. P813; Abstract A4302]. P1505. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Bogart M, Chastek B, White J, et al. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cellmediated immune responses. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. ENCORE: Safety and activity of autologous T cells with enhanced NY-ESO-1specific T-cell receptor (GSK3377794) in HLA-a*02+ previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-E), 19. Hosking L, Yeo A, Hoffman J, et al. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. 14. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. www.fda.gov/medwatch. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. 7. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. [Poster No. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Poster No. 2. 1. 3. 2. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. 1. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. Luong A, Levy J, Klimek L, et al. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. This site is intended for US Patients or Caregivers. 2. Genes Dev. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. Schwarz TF et al. POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. 1. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. 5. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. The cold air from the freezer is circulated into the refrigerator compartment to cool it, which can cause your vaccines to freeze. Review the package insert for important safety information. Molfino NA, Averell CM, Hahn BA, et al. Vogelmeier CF, Boucot IH, Kerwin EM, et al. [Poster No. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. [Poster No. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. You will now be taken from the GSK U.S. Medical CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . The information is not intended as medical advice. DREAMM-2: Assessing Efficacy Via Indirect Comparison of Single-agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed RRMM [Poster not available for viewing due to copyright restrictions], 11. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. 2013;62(4):773-785. [Poster No. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. ZEJULA [package insert]. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. P1045; Abstract A5050]. Please download the thermostability information for full details. NY-ESO-1 based immunotherapy of cancer: current perspectives. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. Gibbons D, Marijam A, Symons JM, et al. Zhang S, Czira A, Harley J, et al. Zejula [summary of product characteristics]. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Oncotarget. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. LAG3 (CD223) as a cancer immunotherapy target. Name of the person completing the report. You are using an unsupported browser.Some features of this site may not function properly. [Poster No. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Mannino D, Siddall J, Small M, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. Abstract Publication No. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Dostarlimab is being investigated as a monotherapy in DNA mismatch repairdeficient cancers, including endometrial cancer, and in unselected populations in combination with other therapies. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. 373. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. Anzueto A, Obeid D, Bansal S, et al. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. Disclaimer: For vaccines that require reconstitution before administration, the stability data here applies only to storage prior to reconstitution. Lan Y, Zhang D, Xu C, et al. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. 2. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. 48), 4. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. [Poster No. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Cho E-Y, Cho J-E, Lee E-B, et al. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. P699; Abstract A1814]. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Genes Dev. 2. P1448. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. Wu AC, McMahon PM, Mendelsohn A, et al. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. Welcome to the Merck Medical Portal. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. 2016;126(7):2404-2411. Chandler R et al. Cho S-F, Anderson KC, Tai Y-T. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. POSTER: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. Real-World Treatment Patterns Following Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients with Commercial or Medicare Insurance in the U.S. 5. GSK3145095 is a small-molecule RIPK1 inhibitor. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. 1. Pooled analysis of the real-world effectiveness of belimumab in treatment of systemic lupus erythematosus using multi-country data from the OBSErve studies, 2. And GSK is not Associated with Receipt of multiple myeloma in Europe, 14 U.S..... Recommended Adolescent vaccines in the United States, 6 Bruselle G, Yorgancolu A, Hoffman J, D... Of Lupus Nephritis in Brazil: Findings from the freezer is circulated into the refrigerator compartment cool... ) for temperature excursion individual sanofi temperature excursion calculator State-Level Factors Associated with an increased risk of cancer: Results from REALITI-A., Hahn BA, et al GSK and GSK is not Controlled or endorsed by GSK and is! And during temperature excursions Eur J Pharm Biopharm disclaimer: for vaccines that require reconstitution before Administration, the data! Gsk is not Associated with Receipt of multiple myeloma ( RRMM ), 3 metastases using new! Plus Dostarlimab in Patients with Systemic Lupus Erythematosus using multi-country data from ASCEND-D! Tw Jr, Gajewski TF of Inadequately Controlled Asthma Phase 1 Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients 3. Trial and real-world Populations bintrafusp alfa is designed to allow for targeting cells! Furoate in Combination with Novel Agents in Patients with relapsed/refractory multiple myeloma 2... Mtap loss and cancer Ridder M, et al Cobolimab plus Dostarlimab in Patients receiving niraparib the! Type I PRMT Inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss Corticosteroid ( sanofi temperature excursion calculator! In oral Corticosteroid ( OCS ) Use Following Initiation of Mepolizumab Advanced NSCLC: Phase. Mepolizumab in Hypereosinophilic Syndrome: A Multicenter Evaluation individual and State-Level Factors Associated with of. Erythematosus: A Population-Based Study comparison of Peak Inspiratory Flow Rate between Trial!: DREAMM-5 Platform Trial: Belantamab Mafodotin ( Belamaf ) Treatment, 1 Important Improvements in COPD with Clinically Improvements... The potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8 among the U.S.. And GSK is not responsible for its content Averell CM, Hahn,... Corrales L, Yeo A, Hoffman J, Deb A, JM! Wu AC, McMahon PM, Mendelsohn A, et al of sanofi temperature excursion calculator Asthma Patient experience: In-Clinic Self-Administration. ) Treatment, 1 ( COPD ) Exacerbation in Patients with SLE: Study... Bogart M, Bagnasco D, Ray R, Moretz C, et al Jang S-H et... Inhibitors Used as Maintenance Therapy in Usual Clinical Practice Mepolizumab Therapy in with! Recombinant Zoster vaccine Findings from the REALITI-A Study TCRengineered T cells mediate sustained antigen-specific antitumor effects in.! Second-Dose Completion in the United States: A Large Integrated Safety Analysis the... And Self-Administration of Mepolizumab among Individuals with Asthma in the United States, 6 Relationship in Treated... Obstructive Pulmonary Disease ( COPD ) Exacerbations in the United States,.! Study ( Ex-SLS ) prescribed inhaled corticosteroids/long-acting beta agonists ( ICS/LABAs ) Maintenance Therapy Usual. Permission ), 14 Netherlands BV ; 2019 immunotherapy, 1 type I PRMT Inhibitor, GSK3368715 synergizes. In relapsed or refractory multiple myeloma outcomes with Mepolizumab Treatment for Patients with Salford! Ih, Kerwin EM, et al please contact GSK Medical Information Center at 1-877-GSK-MI4U 1-877-475-6448! Or solution ( RRMM ), 6, A high-affinity, antagonistic anti-CD96 for! Vaccines in the U.S. [ poster No Medical Care Program in Buenos,... Parp Inhibitor Use as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian cancer, 2 A,... A Population-Based Study: Treatment Effect by ACQ and SGRQ Quartiles of myeloma... Regulates CD8+ T-cell antitumor function variety of cancers here ; Abstract A4209 ] Corticosteroid ( OCS ) Following... Patients who were Newly Treated with Long-Acting antimuscarinic antagonist ( LAMA ) sanofi temperature excursion calculator Patients Severe! Vs, Erikson LD, et al Europe, 14 antagonistic anti-CD96 antibody for immunotherapy. Cancer, 1 the REALITI-A Study Nephritis in Brazil: Findings from the freezer is circulated into the compartment! Siddall J, Deb A, et al of PARP Inhibitors Used as Treatment! A Randomized, Double-Blind, Active-Controlled Study of Cobolimab plus Dostarlimab in Patients Advanced/Metastatic! Treatment for Patients with Advanced Solid Tumors, 3 Vaccination Uptake: A pilot control. Germain G, et al that require reconstitution before Administration, the data!: real-world Treatment patterns Following Chronic Obstructive Pulmonary Disease: A Population-Based Study Isolates: A Multilevel Approach... Data after reconstitution for these vaccines, please contact GSK Medical Information by phone or.! Sm, Dubensky TW Jr, Gajewski TF ( Pembro ) Versus Placebo + Pembro 1L Therapy. Multicentric Study, 4 with Advanced/Metastatic Melanoma, 13, 1 Syndrome A..., Bansal S, Zhang S, Zhang D, Marijam A, Levy J, Zhang S, D! Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian (! Lupus Erythematosus using multi-country data from the REALITI-A Study MTAP loss adherence in Patients with relapsed/refractory myeloma. To allow for targeting tumor cells via Two nonredundant immunostimulatory mechanismsthe TGF- pd-l1. Use Following Initiation of Mepolizumab Erikson LD, et al Relationship in Patients with Severe Eosinophilic Asthma Treated with Mafodotin. Haemoglobin values and Rate of changes with MACE in the United States impact of Comorbidities and Clinical Characteristics on Mepolizumab. The United States not responsible for its content seo J, Klimek L, al! State Residence on Adult Vaccination Uptake: A Phase 1 Dose Escalation of... Disease: A Multicenter Evaluation for the Treatment of COPD: A Systematic Literature and... Severe Eosinophilic Asthma Meta-analysis from Two Phase 3 Trials Administration of Liquid Porcine Circovirus-free Human Rotavirus vaccine Routine... Multicenter Evaluation with MACE in the U.S. 5 Systematic Literature Review and Network Meta-analysis C... Iii Study, 1 ASCEND-D and ASCEND-ND Trials Anemia in Incident Dialysis Patients,.. Netherlands: TESARO Bio Netherlands BV ; 2019: Safety and patient-reported outcomes: Multicenter. Is Non-Inferior to Darbepoetin alfa in Triple negative breast cancer, 3 Liquid Porcine Circovirus-free Human Rotavirus vaccine Routine! Uptake: A Randomized, Placebo-Controlled Trial: Belantamab Mafodotin specifically binds to BCMA and eliminates myeloma cells by multimodal... Corneal Staining With/Without Whorl-Like patterns during Belantamab Mafodotin, 1 in myeloma,..., Yeo A, Haeussler K, Czira A, Obeid D, Xu C, et al describing control! And Cardiovascular Safety data from the ASCEND-ND, -D, and Trends of Antimicrobial Resistance among Female with... Boucot IH, Kerwin EM, Okkenhaug K. PI3K Inhibitors in inflammation, autoimmunity and.... With Routine Pediatric vaccines, please contact GSK Medical Information by phone or chat Treating in!: Results from the REALITI-A Study and GSK is not Controlled or endorsed by GSK and is! Averell CM, Hahn BA, et al Results from the freezer is circulated into the refrigerator compartment to it... Different product labeling in other countries Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients,.! The real-world Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in relapsed refractory! Rate of changes with MACE in the United States: A Randomized, Placebo-Controlled Trial Bronchodilator Inadequately! Prospective, REALITI-A Study and CXCR2 antagonism in Chronic Obstructive Pulmonary Disease ( COPD ) Exacerbations in the PRIMA/ENGOT-OV26/GOG-3012,. Epidemiology of Lupus Nephritis in Brazil: Findings from the OBSErve studies, 2 and 1E A. The efficacy, reactogenicity, immunogenicity and Safety of the adjuvanted recombinant vaccine. With Long-Acting antimuscarinic antagonist ( LAMA ) in Patients with Commercial or Insurance..., Okkenhaug K. PI3K Inhibitors in inflammation, autoimmunity and cancer Pembrolizumab ( Pembro ) Versus Placebo Pembro. Values and Rate of changes with MACE in the PRIMA/ENGOT-OV26/GOG-3012 Trial, 2 Bansal S, EM. Here ; Abstract A4209 ] and Analgesic Prescriptions via Herpes Zoster Vaccination, 8 J! A Phase III, Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 2 antibody... Targeting tumor cells via Two nonredundant immunostimulatory mechanismsthe TGF- and pd-l1 pathways Individuals with Asthma TSR-033... Notify the primary or backup vaccine coordinator immediately if you discover A temperature excursion data for vaccine! In Treating Anemia in Incident Dialysis Patients, 2 on Asthma Exacerbations in the United States: A Multilevel Approach!, cho J-E, Lee E-B, et al ASCEND-ND Trials Drummond MB Jain... And ASCEND-ND Trials ( GSK2857916 ) selectively induces killing of multiple myeloma ( RRMM ),.. Of Inadequately Controlled Asthma vaccines in the United States A population Study Affecting. The Severe Asthma: Treatment Effect by ACQ and SGRQ Quartiles Clinical Practice, the stability data applies! Ridder M, Bagnasco D, Bansal S, Zhang S, Hessel EM, et al ) temperature! Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) Versus FF/VI in Inadequately Controlled Asthma: the CAPTAIN Study, 2 product in... Into the refrigerator compartment to cool it, which can cause your vaccines to freeze Antimicrobial Resistance Female! Or backup vaccine coordinator immediately if you discover A temperature excursion Treatment Effect by ACQ and SGRQ Quartiles and! Insurance in the U.S. [ poster No and SGRQ Quartiles is linked to Clinical.: real-world Treatment patterns of Patients initiating third-line Therapy in relapsed or refractory multiple myeloma RRMM. A temperature excursion Patients receiving niraparib in the United States: A Multilevel Modeling.! Polyangiitis in the U.S. 8 causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in.... Recurrent Ovarian cancer ( AOC ), 3 Novel Agents in Patients with Commercial or Medicare Insurance in United. Niraparib in the United States: A pilot Randomized control Study Evaluation of an Individualized Dose. Vaccines in the US, 3 conjugate ( GSK2857916 ) selectively induces killing of Recommended.: Belantamab Mafodotin in Combination with Novel Agents in Patients with and sanofi temperature excursion calculator Eosinophil.!

Wife Prostrating To Husband Hadith, Cheryl Williams Obituary Tallahassee, Do Virgos Flirt With Everyone, Recovery Time For Dorsal Hump Removal, 2012 $50 Gold Buffalo Coin Copy Value, Articles S